FDA Approves Genentech's Enspryng for Thyroid Eye Disease as an Injection Patients Can Give at Home
Genentech said the FDA approved Enspryng for adults with thyroid eye disease. One of its two Phase 3 trials met its main goal and the other did not, according to the drug's label.
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources
Brief
Genentech said on Oct. 15, 2026, that the U.S. Food and Drug Administration had approved Enspryng (satralizumab-mwge) for adults with thyroid eye disease, an autoimmune…
More reporting and context continue here.
The complete story is available with Premium.
Read the facts, open questions and supporting sources.
Continue reading with NewsPlain Premium.
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.